Chloroquine and Hydroxychloroquine in Coronavirus Disease-19: The Real Savior or a False-positive Testament

IF 0.4 Q4 PHARMACOLOGY & PHARMACY Asian Journal of Pharmaceutics Pub Date : 2021-03-17 DOI:10.22377/AJP.V15I1.3936
M. Iqbal
{"title":"Chloroquine and Hydroxychloroquine in Coronavirus Disease-19: The Real Savior or a False-positive Testament","authors":"M. Iqbal","doi":"10.22377/AJP.V15I1.3936","DOIUrl":null,"url":null,"abstract":"Objective: A novel coronavirus disease (COVID-19) has spread all around the world. The progression from initial signs to a diagnosis of acute respiratory failure is usually related to spontaneous cytokine production. There is a growing need to classify appropriate medicines for treatment care. The inhibitory effect of chloroquine (CQ) is potential. However, CQ can lead to serious side effects. Various studies recommend hydroxychloroquine (HCQ) have similar antiviral effect as of CQ and maybe a better therapeutic solution. Therefore, we aim to explore the mechanism by which HCQ can inhibit replication of coronavirus. Materials and Methods: A retrospective study was carried out using online databases from 2003 to 2020. Results: The obtained results showed that HCQ can inhibit viral replication and entry inside the cell through raising lysosomal pH and binding to specific receptors on the cells, thereby, preventing viral entry. Conclusion: HCQ has a better safety profile than CQ and also modulates cytokine syndrome. However, further studies are needed to explore this mechanism.","PeriodicalId":8489,"journal":{"name":"Asian Journal of Pharmaceutics","volume":null,"pages":null},"PeriodicalIF":0.4000,"publicationDate":"2021-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"36","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Asian Journal of Pharmaceutics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.22377/AJP.V15I1.3936","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 36

Abstract

Objective: A novel coronavirus disease (COVID-19) has spread all around the world. The progression from initial signs to a diagnosis of acute respiratory failure is usually related to spontaneous cytokine production. There is a growing need to classify appropriate medicines for treatment care. The inhibitory effect of chloroquine (CQ) is potential. However, CQ can lead to serious side effects. Various studies recommend hydroxychloroquine (HCQ) have similar antiviral effect as of CQ and maybe a better therapeutic solution. Therefore, we aim to explore the mechanism by which HCQ can inhibit replication of coronavirus. Materials and Methods: A retrospective study was carried out using online databases from 2003 to 2020. Results: The obtained results showed that HCQ can inhibit viral replication and entry inside the cell through raising lysosomal pH and binding to specific receptors on the cells, thereby, preventing viral entry. Conclusion: HCQ has a better safety profile than CQ and also modulates cytokine syndrome. However, further studies are needed to explore this mechanism.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
氯喹和羟氯喹在冠状病毒疾病-19:真正的救世主或假阳性的遗嘱
目的:一种新型冠状病毒病(COVID-19)已在全球蔓延。从最初的症状到诊断急性呼吸衰竭的进展通常与自发细胞因子的产生有关。越来越需要对用于治疗和护理的适当药物进行分类。氯喹(CQ)具有潜在的抑制作用。然而,CQ会导致严重的副作用。各种研究表明羟氯喹(HCQ)具有与羟氯喹相似的抗病毒作用,可能是一种更好的治疗方案。因此,我们的目的是探索HCQ抑制冠状病毒复制的机制。材料与方法:采用2003 - 2020年在线数据库进行回顾性研究。结果:所得结果表明,HCQ可以通过提高溶酶体pH值和与细胞上的特异性受体结合,从而抑制病毒的复制和进入细胞,从而阻止病毒进入。结论:HCQ比CQ具有更好的安全性,并能调节细胞因子综合征。然而,需要进一步的研究来探索这一机制。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Asian Journal of  Pharmaceutics
Asian Journal of Pharmaceutics PHARMACOLOGY & PHARMACY-
自引率
0.00%
发文量
47
期刊介绍: Character of the publications: -Pharmaceutics and Pharmaceutical Technology -Formulation Design and Development -Drug Discovery and Development Interface -Manufacturing Science and Engineering -Pharmacokinetics, Pharmacodynamics, and Drug Metabolism -Clinical Pharmacology, General Medicine and Translational Research -Physical Pharmacy and Biopharmaceutics -Novel Drug delivery system -Biotechnology & Microbiological evaluations -Regulatory Sciences
期刊最新文献
A Design of Experiment-based Approach for the Formulation Development and Evaluation of Repaglinide Transdermal Patch Using Natural Polymers Modification of Human Behavior due to Coronavirus Outbreak: A Brief Study on Current Scenario Formulation and Evaluation of Sustained Release Bilayer Tablets of Losartan Potassium Bioanalytical Method Development and Validation of Empagliflozin by LC–MS/MS Method and Quantitative Estimation of Drug Concentration in Human Plasma Formulation and Evaluation of Antidiabetic Polyherbal Tablets
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1